SCHEMBL16216296

SCHEMBL16216296

CC(=N)NCc1ccc(C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ LMNA P02545 2/20 0.53
▸ NPC1 O15118 4/20 0.52
▸ MAPT P10636 2/20 0.49
▸ KMT2A Q03164 8/20 0.47
▸ MEN1 O00255 7/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ HSP90AB1 P08238 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ BLM P54132 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7865708 0.91 KMT2A (0.47) SMN1; SMN2LMNANPC1MAPTKMT2A
SCHEMBL16216177 0.81 PLA2G1B (0.59) LMNANPC1KMT2AALDH1A1RAB9A
SCHEMBL7865745 0.81 TPSAB1 (0.57) —
SCHEMBL4100287 0.81 IDO1 (0.52) SMN1; SMN2LMNANPC1MAPTKMT2A
SCHEMBL16216165 0.81 KMT2A (0.40) SMN1; SMN2LMNANPC1MAPTKMT2A
SCHEMBL20113982 0.81 SMN1; SMN2 (0.52) SMN1; SMN2LMNANPC1MAPTKMT2A
SCHEMBL14355138 0.81 MEN1 (0.59) SMN1; SMN2NPC1MAPTKMT2AMEN1
SCHEMBL13879953 0.81 CYP2C9 (0.41) LMNAMAPTKMT2AMEN1ALDH1A1
SCHEMBL13120816 0.80 ALOX12 (0.56) SMN1; SMN2LMNAMAPTKMT2AMEN1
SCHEMBL27462347 0.80 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-09-21 — — US disclosed
US-9550000-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2017-01-24 — — US disclosed
US-20140328756-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 148/4885LMNA 1311/4885NPC1 988/4885
US-20140328756-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 148/4885LMNA 1311/4885NPC1 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback